Mergers & Acquisitions Mergers & Acquisitions

Novartis files MorphoSys takeover for Austrian approval

By Andrew Boyce
  • 13 Feb 2024 11:08
  • 13 Feb 2024 11:08
Novartis has filed its plan to buy MorphoSys, a developer of cancer treatments, for approval in Austria.
The Austrian competition watchdog has until March 11 to decide whether to clear the deal or refer it to the national cartel court for an in-depth review.

Swiss drugmaker Novartis announced last

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Andrew Boyce


Andrew is a reporter covering merger reviews and competition policy for MLex in Brussels. He joined MLex in 2015 and holds a degree and a master’s degree in history from the University of Liverpool.

Discover MLex

Stay on top of global regulatory developments

Latest News